13-cis-Acitretin
13-cis-Acitretin structure
|
Common Name | 13-cis-Acitretin | ||
|---|---|---|---|---|
| CAS Number | 69427-46-9 | Molecular Weight | 326.429 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 521.3±38.0 °C at 760 mmHg | |
| Molecular Formula | C21H26O3 | Melting Point | 228-230ºC | |
| MSDS | N/A | Flash Point | 180.3±20.3 °C | |
|
Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
J. Am. Acad. Dermatol. 71(6) , 1167-75, (2014) The effectiveness of psoriasis therapies in real-world settings remains relatively unknown.We sought to compare the effectiveness of less commonly used systemic therapies and commonly used combination therapies for psoriasis.This was a multicenter cross-secti... |
|
|
Acitretin exhibits inhibitory effects towards UDP-glucuronosyltransferase (UGT)1A9-mediated 4-methylumbelliferone (4-MU) and propofol glucuronidation reaction.
Pharmazie 68(6) , 449-52, (2013) The present study aimed to evaluate the potential risk of drug-drug interactions associated with acitretin which is a drug for therapy of psoriasis approved by the Food and Drug Administration (FDA). The initial screening of acitretin's inhibition towards 4-m... |
|
|
IgA pemphigus: case series with emphasis on therapeutic response.
J. Am. Acad. Dermatol. 70(1) , 200-1, (2014)
|
|
|
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
J. Am. Acad. Dermatol. 70(1) , 168-77, (2014) Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD.We reviewed the literature to define the impact of common psoriasis therapies o... |
|
|
Complete and rapid regression of primary cutaneous follicular lymphoma with repeated oral administration of acitretin for palmoplantar psoriasis.
J. Am. Acad. Dermatol. 69(4) , e176-7, (2013)
|
|
|
A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
JAMA Dermatol. 149(3) , 279-81, (2013)
|
|
|
Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod.
Journal. of. Drugs in. Dermatology. 12(3) , 348-9, (2013) Increased cases of acquired epidermodysplasia verruciformis (EDV) have been reported in patients with human immunodeficiency virus (HIV). With regard to management, there are no randomized controlled trials in either immunocompetent or immunocompromised patie... |
|
|
Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skin.
J. Am. Acad. Dermatol. 69(3) , 426-30, (2013) There is no known association between the development of keratoacanthomas and prurigo nodules.We report a case series of 7 patients with a long-standing history of actinic damage, pruritus, and prurigo nodularis who developed widespread keratoacanthomas withi... |
|
|
Acitretin: no pregnancy during treatment and, as a precaution, for 3 years after discontinuation.
Prescrire Int. 22(141) , 213, (2013)
|
|
|
[Patient with lichen ruber planus. How should it be treated?].
MMW Fortschr. Med. 155(2) , 26, (2013)
|